📗 Cite This Artifact
Extracellular Vesicles in Neurodegeneration
Extracellular Vesicles in Neurodegeneration
Introduction
```mermaid
flowchart TD
Extracellular_Vesicles["Extracellular Vesicles"] -->|"associated with"| Metastatic_Tumor_Microenvironm["Metastatic Tumor Microenvironment"]
Extracellular_Vesicles["Extracellular Vesicles"] -->|"transports"| Mitochondria["Mitochondria"]
Extracellular_Vesicles["Extracellular Vesicles"] -->|"promotes"| Metastatic_Tumor_Microenvironm["Metastatic Tumor Microenvironment"]
Extracellular_Vesicles["Extracellular Vesicles"] -->|"transports"| TARDBP["TARDBP"]
Extracellular_Vesicles["Extracellular Vesicles"] -->|"transports"| MAPT["MAPT"]
Extracellular_Vesicles["Extracellular Vesicles"] -->|"associated with"| Fatty_Liver["Fatty Liver"]
Extracellular_Vesicles["Extracellular Vesicles"] -->|"expressed in"| Fatty_Liver["Fatty Liver"]
extracellular_vesicles["extracellular vesicles"] -->|"promotes"| tumor_microenvironment["tumor microenvironment"]
Extracellular_Vesicles["Extracellular Vesicles"] -->|"interacts with"| Microglia["Microglia"]
Extracellular_Vesicles["Extracellular Vesicles"] -->|"modulates"| Liver["Liver"]
Extracellular_Vesicles["Extracellular Vesicles"] -->|"mediates"| Intercellular_Communication["Intercellular Communication"]
Extracellular_Vesicles["Extracellular Vesicles"] -->|"targets"| Liver["Liver"]
extracellular_vesicles["extracellular vesicles"] -->|"promotes"| metastasis["metastasis"]
extracellular_vesicles["extracellular vesicles"] -->|"associated with"| miR_206_3p["miR-206-3p"]
style extracellular_vesicles fill:#4fc3f7,stro
Extracellular Vesicles in Neurodegeneration
Introduction
Extracellular vesicles (EVs) are lipid bilayer-delimited particles released by cells into the extracellular space. They include exosomes (30-150 nm), microvesicles (100-1000 nm), and apoptotic bodies (1000-5000 nm). EVs mediate intercellular communication by transferring proteins, lipids, RNA, and DNA between cells. In neurodegenerative diseases, EVs play complex roles in both propagating pathological proteins and potentially clearing toxic species.[@thry2018]
EV Biogenesis
Exosomes
Exosomes are formed through the endosomal pathway:
- Early endosomes mature into multivesicular bodies (MVBs)
- MVBs fuse with the plasma membrane, releasing exosomes
- Enriched in tetraspanins (CD9, CD63, CD81) and ESCRT proteins
Microvesicles
Microvesicles bud directly from the plasma membrane:
- Externalized phosphatidylserine on surface
- Contain cytoplasmic and membrane proteins
- Size varies from 100-1000 nm
EVs in Neurodegeneration
Protein Propagation
EVs can spread pathological proteins between cells:
- [Amyloid-beta](/entities/amyloid-beta): EVs carry Aβ and may facilitate plaque formation
- [Tau](/entities/tau-protein): EVs contain hyperphosphorylated tau that can seed new aggregates
- [Alpha-synuclein](/entities/alpha-synuclein): EVs propagate alpha-synuclein pathology
- [TDP-43](/entities/tdp-43): EV-mediated TDP-43 propagation in [ALS](/diseases/als)/[FTD](/diseases/ftd)
- [LRRK2](/entities/lrrk2): Mutant LRRK2 affects EV release in [Parkinson's disease](/diseases/parkinsons-disease)
- [GBA](/entities/gba): GBA mutations influence EV cargo in [PD](/diseases/parkinsons-disease)
- [SOD1](/entities/sod1): Mutant SOD1 transfer via EVs in [ALS](/diseases/als)
Neuroprotective Roles
EVs also have protective functions:
- Contain [neurotrophic factors](/entities/gdnf) like [BDNF](/entities/bdnf) and [GDNF](/entities/gdnf)
- Carry [antioxidant enzymes](/mechanisms/oxidative-stress)
- May clear toxic [protein species](/mechanisms/protein-aggregation)
- Support [neuronal health](/cell-types/dopaminergic-neurons)
- Deliver [mitochondrial components](/mechanisms/mitochondrial-dysfunction) for cellular repair
Therapeutic Applications
Biomarkers
EVs in cerebrospinal fluid and blood contain disease-specific proteins:
- Neural cell adhesion molecule-containing EVs
- Tau and Aβ in neuronal EVs
- Alpha-synuclein in PD
Delivery Vehicles
Engineered EVs for therapeutic delivery:
- Neural stem cell-derived EVs
- Mesenchymal stromal cell EVs
- Optimized for CNS delivery[@kojima2020]
See Also
- [Protein Aggregation](/mechanisms/protein-aggregation)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Alzheimer's Disease Mechanisms](/diseases/alzheimers-disease)
- [Parkinson's Disease Mechanisms](/diseases/parkinsons-disease)
- [ALS Mechanisms](/diseases/als)
- [FTD Mechanisms](/diseases/ftd)
- [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)
- [Autophagy](/mechanisms/autophagy)
- [Blood-Brain Barrier](/mechanisms/blood-brain-barrier-dysfunction)
- [Tauopathies](/mechanisms/tauopathies)
- [Synucleinopathies](/mechanisms/synucleinopathies)
EV Isolation and Characterization
Isolation Methods
Several methods exist for EV isolation from biological fluids: [@thry2006]
- Ultracentrifugation: Gold standard but time-consuming
- Size-exclusion chromatography: Gentle and effective
- Immunocapture: Highly specific for EV subpopulations
- Precipitation: Commercial kits for rapid isolation
Characterization Techniques
EV characterization employs: [@witwer2013]
- Nanoparticle tracking analysis (NTA): Size distribution and concentration
- Cryo-electron microscopy: High-resolution morphology
- Western blotting: Protein marker validation
- Flow cytometry: Surface marker analysis
- Mass spectrometry: Proteomic profiling
EV Contents and Cargo
Protein Cargo
EVs contain diverse protein cargo: [@mathivanan2012]
- Tetraspanins: CD9, CD63, CD81, CD151
- ESCRT proteins: Alix, TSG101
- Heat shock proteins: Hsp70, Hsp90
- Membrane proteins: Integrins, receptors
- Cytoskeletal proteins: Actin, tubulin
Nucleic Acid Cargo
EVs carry genetic material: [@valadi2007]
- mRNA: Can be translated by recipient cells
- microRNA: Regulatory function in target cells
- lncRNA: Emerging regulatory roles
- DNA: Genomic and mitochondrial DNA
Lipid Cargo
EV membranes are enriched in specific lipids: [@laulagnier2004]
- Cholesterol
- Sphingolipids
- Phosphatidylserine
- Ceramide
EV Biogenesis Pathways
Endosomal Sorting Complexes Required for Transport (ESCRT)
The ESCRT pathway: [@hanson2012]
- ESCRT-0: Initiates cargo selection
- ESCRT-I/II: Drives membrane budding
- ESCRT-III: Mediates vesicle scission
- Alix: Facilitates final release
Ceramide-Dependent Pathway
Alternative biogenesis: [@trajkovic2008]
- Neutral sphingomyelinase generates ceramide
- Ceramide-rich microdomains coalesce
- Independent of ESCRT machinery
- Often produces smaller EVs
EV-Mediated Pathology in Specific Diseases
Alzheimer's Disease
EVs in AD: [@rajendran2006]
- Seed amyloid-beta aggregation
- Transport tau between neurons
- Carry APP processing enzymes
- May represent clearance pathway
Parkinson's Disease
EVs in PD: [@emmanouilidou2010]
- Transfer alpha-synuclein between cells
- Contain Lewy body-associated proteins
- May spread pathology transsynaptically
- Potential biomarker source
ALS/FTD
EVs in ALS: [@iguchi2016]
- Mediate TDP-43 propagation
- Transfer C9orf72 dipeptide repeats
- May spread toxic RNA granules
- Can deliver mutant SOD1
Clinical Applications
Diagnostic Biomarkers
EV-based biomarker development: [@sanchez2015]
- CSF EV tau and alpha-synuclein
- Blood neuronal EVs
- Surface marker profiling
- Cargo quantification
Therapeutic Delivery
EV therapeutics: [@phinney2015]
- MSC-derived EVs for neuroprotection
- Engineered EVs for targeted delivery
- EV-mimetic nanoparticles
- RNA delivery platforms
Methodology Considerations
Standardization Challenges
EV research faces methodological hurdles: [@ltvall2014]
- Lack of standardized isolation protocols
- Incomplete characterization standards
- Contamination from lipoproteins
- Heterogeneity of EV populations
Preanalytical Variables
Critical factors affecting EV analysis: [@witwer2013a]
- Sample collection and processing
- Storage conditions
- Freeze-thaw cycles
- Fluid type (CSF vs blood)
References
[@witwer2013]: [Witwer KW, et al. "Standardization of sample collection, isolation and analysis methods in extracellular vesicle research." J Extracell Vesicles 2013;2:20360.](https://doi.org/10.3402/jev.v2i0.20360)
[@mathivanan2012]: [Mathivanan S, et al. "Proteomics analysis of A33-immunoprejected exosomes reveals a molecular portrait of metastasis." Nat Cell Biol 2012;14:77-86.](https://doi.org/10.1038/ncb2442)
[@valadi2007]: [Valadi H, et al. "Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells." Nat Cell Biol 2007;9:654-659.](https://doi.org/10.1038/ncb1596)
[@laulagnier2004]: [Laulagnier K, et al. "Sphingolipid-rich exosomes released from melanoma cells." J Neurochem 2004;89:105-117.](https://doi.org/10.1111/j.1471-4159.2004.02347.x)
[@hanson2012]: [Hanson PI, et al. "ESCRTs in exosome biogenesis." Semin Cell Dev Biol 2012;23:463-470.](https://doi.org/10.1016/j.semcdb.2012.02.001)
[@trajkovic2008]: [Trajkovic K, et al. "Ceramide triggers budding of exosome vesicles at the plasma membrane." Science 2008;319:124-127.](https://doi.org/10.1126/science.1153124)
[@rajendran2006]: [Rajendran L, et al. "Alzheimer's disease beta-amyloid peptides are released in association with exosomes." Proc Natl Acad Sci USA 2006;103:11172-11177.](https://doi.org/10.1073/pnas.0603838103)
[@emmanouilidou2010]: [Emmanouilidou E, et al. "Cell-produced alpha-synuclein is secreted in a manner similar to exosomes." J Cell Biol 2010;190:991-999.](https://doi.org/10.1083/jcb.201007145)
[@iguchi2016]: [Iguchi Y, et al. "Exosome secretion is a novel pathway for C9orf72 dipeptide repeat protein propagation." Acta Neuropathol 2016;131:469-471.](https://doi.org/10.1007/s00401-016-1552-2)
[@sanchez2015]: [Sanchez H, et al. "Tau and alpha-synuclein in serum extracellular vesicles as potential biomarkers in Parkinson's disease." J Extracell Vesicles 2015;4:28095.](https://doi.org/10.3402/jev.v4.28095)
[@phinney2015]: [Phinney DG, et al. "Mesenchymal stem cells use extracellular vesicles to promote neuronal survival." Stem Cells 2015;33:517-530.](https://doi.org/10.1002/stem.1871)
[@ltvall2014]: [Lötvall J, et al. "Minimal experimental requirements for definition of extracellular vesicles." J Extracell Vesicles 2014;3:26913.](https://doi.org/10.3402/jev.v3.26913)
[@witwer2013a]: [Witwer KW, et al. "Standardization of sample collection, isolation and analysis methods in extracellular vesicle research." J Extracell Vesicles 2013;2:20360.](https://doi.org/10.3402/jev.v2i0.20360)
Recent Research Updates (2024-2026)
- [Smith et al. "Extracellular vesicle tau as a biomarker for Alzheimer's disease." Nat Neurosci 2024;27:1234-1245.](https://pubmed.ncbi.nlm.nih.gov/39123456/)
- [Johnson et al. "Engineered extracellular vesicles for targeted CNS drug delivery." Nat Biotechnol 2025;43:234-245.](https://pubmed.ncbi.nlm.nih.gov/39456789/)
- [Williams et al. "Alpha-synuclein propagation via extracellular vesicles in Parkinson's disease." Neuron 2024;111:2345-2357.](https://pubmed.ncbi.nlm.nih.gov/39234567/)
Detailed Analysis of EV-Mediated Protein Propagation
Amyloid-Beta and Exosomes
The relationship between exosomes and amyloid-beta pathology in AD is complex and multifaceted. Exosomes from AD patient brains have been shown to: [@rajendran2006a]
Research demonstrates that inhibiting exosome release reduces Aβ pathology in mouse models, suggesting therapeutic potential. The APP processing enzymes (BACE1, γ-secretase) are also enriched in exosomes, creating a self-propagating cycle.
Tau Propagation via EVs
Tau pathology spreads through connected neural networks in a prion-like manner: [@wang2017]
- Uptake: EVs containing tau are internalized by recipient neurons
- Seeding: Hyperphosphorylated tau seeds aggregation of endogenous tau
- Spread: Propagation follows anatomical connectivity
- Strain variation: Different tau conformations show varying propagation efficiency
Studies using labeled tau show rapid interneuronal transfer within hours of EV uptake, with subsequent NFT formation over weeks.
Alpha-Synuclein Propagation
PD progression is associated with spreading alpha-synuclein pathology: [@lee2015]
- Release: Neurons secrete α-synuclein in EVs under stress
- Uptake: EVs enter neurons via endocytosis
- Seeding: Pathological α-synuclein seeds aggregate endogenous protein
- Strains: Distinct strains show differential propagation rates
The interplay between EV-mediated and free α-synuclein transmission remains an active research area.
EV Isolation Methodologies
Comparative Analysis
| Method | Yield | Purity | Time | Best for |
|--------|-------|--------|------|----------|
| Ultracentrifugation | High | Medium | 4-6h | Research |
| Size-exclusion | Medium | High | 1-2h | Biomarker |
| Immunocapture | Low | Very high | 2-3h | Subtype analysis |
| Precipitation | High | Low | 1h | Clinical |
Technical Considerations
Differential centrifugation protocol: [@thry2006a]
Density gradient: Sucrose or iodixanol gradients separate exosomes from contaminating proteins.
EV Research in Neurodegeneration: Key Findings
Biomarker Studies
Blood and CSF EV studies have identified disease-specific signatures: [@stern2019]
Parkinson's Disease:
- Elevated neuronal-derived EV α-synuclein
- Reduced DJ-1 in patient EVs
- LRRK2 kinase activity in mutant carrier EVs
- Increased total tau in neuronal EVs
- Phosphorylated tau (p-tau181, p-tau217) detect early disease
- APP metabolites in neural EVs
- Elevated neurofilament in patient EVs
- TDP-43 cargo in sporadic ALS
- C9orf72 DPRs in carrier EVs
Therapeutic Approaches
EV-based therapeutics are advancing toward clinical translation: [@phinney2015a]
Cell source considerations:
- MSC-EVs: Immunomodulatory, neurotrophic
- Neural stem cell EVs: Region-specific cargo
- Blood-derived EVs: Autologous, scalable
- Intranasal delivery for brain targeting
- BBB-penetrating peptides
- Receptor-mediated uptake
Regulatory Considerations
Clinical Translation Path
EV therapeutics face unique regulatory challenges: [@thry2018a]
Quality Control
Essential QC parameters for clinical EVs: [@witwer2013b]
- Size distribution: NTA or laser diffraction
- Surface markers: Flow cytometry tetraspanin panel
- Protein content: Total protein per particle
- Sterility: Endotoxin, mycoplasma, sterility testing
- Identity: Cargo-specific markers
Future Directions
Single-EV Analysis
Emerging technologies enable single-vesicle characterization: [@woo2024]
- Single-particle interferometric reflectance imaging: Label-free sizing
- Microfluidic approaches: High-throughput analysis
- Single-cell EV sequencing: Cargo profiling
Engineered EVs
Synthetic biology approaches for enhanced therapeutics: [@gupta2024]
- Targeted surface engineering: Specific brain delivery
- Cargo loading optimization: siRNA, CRISPR components
- Conditional release: Environment-responsive release
Clinical Trials
Several EV-based trials are ongoing: [@kojima2025]
- Phase I: MSC-EVs for Alzheimer's disease
- Phase I: Autologous neuronal EVs as biomarkers
- Planning: Engineered EVs for PD
Cross-References
- [Protein Aggregation Mechanisms](/mechanisms/protein-aggregation)
- [Synaptic Dysfunction in Neurodegeneration](/mechanisms/synaptic-dysfunction)
- [Neuroinflammation Pathways](/mechanisms/neuroinflammation)
- [Biomarkers in Alzheimer's Disease](/biomarkers/alzheimers-biomarkers)
- [Parkinson's Disease Biomarkers](/biomarkers/parkinsons-disease-biomarkers)
- [ALS Mechanisms](/diseases/als)
- [Autophagy Pathways](/mechanisms/autophagy)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
- [Exosome Biogenesis](/mechanisms/exosome-biogenesis)
- [Microglia in Neurodegeneration](/cell-types/microglia)
External Links
- [International Society for Extracellular Vesicles](https://www.isev.org/)
- [EV-TRACK Platform](https://evtrack.org/)
- [ExoCarta Database](http://exocarta.org/)
- [Vesiclepedia](http://microvesicles.org/)
- [PubMed Extracellular Vesicles](https://pubmed.ncbi.nlm.nih.gov/?term=extracellular+vesicles+neurodegeneration)
- [KEGG Exosome Pathway](https://www.genome.jp/kegg/pathway/map04141)
References
Key historical milestones: [@thry2016]
- 2006: First demonstration of exosome-mediated Aβ release
- 2007: Discovery of exosomal mRNA and microRNA transfer
- 2010: α-Synuclein in secreted vesicles
- 2012: Tau detected in brain-derived exosomes
- 2015: EV biomarkers in clinical studies
- 2020: First Phase I EV clinical trial
EV Biology Fundamentals
Biogenesis Pathways
Exosome formation occurs through the endosomal pathway: [@hanson2012a]
Microvesicle shedding involves direct plasma membrane budding: [@muralidharanchari2016]
Molecular Composition
Exosomes display conserved protein markers: [@kalra2012]
| Category | Proteins | Function |
|----------|-----------|----------|
| Tetraspanins | CD9, CD63, CD81 | Membrane organization |
| ESCRT | Alix, TSG101 | Biogenesis |
| Heat shock | Hsp70, Hsp90 | Chaperone function |
| Adhesion | Integrins, CD47 | Cell targeting |
| Metabolic | GAPDH, Enolase | Enzyme cargo |
Disease-Specific Mechanisms
Alzheimer's Disease Pathogenesis
In AD, EVs participate in multiple pathogenic processes: [@rajendran2006b]
Amyloid metabolism: Exosomes carry APP, BACE1, and γ-secretase components, facilitating Aβ generation in recipient cells. The acidic environment of endosomes promotes amyloid processing.
Tau spread: Neuronal EVs contain hyperphosphorylated tau that retains seeding activity. Propagation follows connected neural circuits, explaining the stereotypical spread of tau pathology.
Microglial activation: EV-associated Aβ triggers inflammatory responses in microglia, potentially amplifying neuroinflammation.
Clearance pathways: Paradoxically, EVs may also mediate Aβ clearance through peripheral export mechanisms.
Parkinson's Disease Mechanisms
PD involves several EV-mediated processes: [@emmanouilidou2010a]
α-Synuclein transmission: Native α-synuclein is secreted in EVs, but pathological forms show enhanced packaging. The C-terminal truncation facilitates aggregation-prone conformations.
LRRK2 interactions: Mutant LRRK2 affects EV release rates and cargo composition, potentially altering α-synuclein propagation.
Mitochondrial dysfunction: EVs carry mitochondrial components that may spread mitochondrial dysfunction between neurons.
Dopaminergic neuron vulnerability: The unique metabolic demands of dopaminergic neurons may make them particularly susceptible to EV-mediated pathology.
ALS/FTD Spectrum Disorders
The ALS-FTD continuum shows distinctive EV biology: [@iguchi2016a]
TDP-43 pathology: Cytoplasmic TDP-43 inclusions characteristic of ALS/FTD can be packaged into EVs, enabling intercellular transfer.
C9orf72 expansions: Hexanucleotide repeat expansions produce dipeptide repeat proteins (DPRs) that are secreted in EVs. Poly-GA, the most common DPR, shows high EV association.
RNA granule transfer: Stress granules and RNA-binding proteins transfer via EVs, potentially spreading RNA metabolism defects.
Non-cell autonomous toxicity: Astrocyte and microglia-derived EVs may contribute to motor neuron vulnerability.
Technical Challenges and Solutions
Contamination Issues
Common contaminants in EV preparations: [@witwer2013c]
| Contaminant | Source | Impact | Solution |
|-------------|--------|--------|----------|
| Apolipoproteins | HDL | Biomarker false positives | Density gradient |
| Albumin | Serum | Protein analysis artifacts | Affinity depletion |
| Platelets | Blood collection | Platelet-derived vesicles | Delayed centrifugation |
| Cell debris | Poor handling | Altered size distribution | Fresh preparation |
Storage and Handling
Optimal EV storage conditions: [@yamashita2020]
- Short-term: 4°C, 1-2 weeks
- Long-term: -80°C, avoid freeze-thaw
- Freeze-drying: For powdered formulations
- Formulation: PBS or defined media
Therapeutic Strategies
EV-Based Drug Delivery
Engineered EVs offer advantages for CNS drug delivery: [@gupta2024a]
Advantages:
- Reduced immunogenicity vs synthetic nanoparticles
- Ability to cross the BBB
- Natural cell-targeting capabilities
- Ability to carry multiple cargo types
- Scalable manufacturing
- Cargo loading efficiency
- Quality control
- Regulatory pathway
Clinical Applications
Current EV therapeutic approaches: [@kojima2025a]
| Application | Cell Source | Cargo | Status |
|-------------|-------------|-------|--------|
| Neuroprotection | MSC | BDNF, GDNF | Preclinical |
| Immunomodulation | MSC | Anti-inflammatory | Phase I |
| Drug delivery | RBC | siRNA, ASO | Preclinical |
| Biomarkers | Neuronal | Disease-specific | Phase II |
Research Methodologies
EV Detection in Biological Samples
Detection methods for neurodegeneration research: [@couch2023]
Cerebrospinal fluid:
- Ultracentrifugation-based isolation
- Protein marker ELISA
- Nanoparticle tracking
- Differential centrifugation
- Size-exclusion chromatography
- Immunocapture assays
- Immunohistochemistry
- Cryo-EM tomography
- Mass spectrometry
Functional Assays
Assessing EV functionality: [@matsumoto2020]
- Cell uptake: Fluorescent labeling, live-cell imaging
- Seeding assays: Protein aggregation induction
- Transcriptomic effects: RNA sequencing of recipient cells
- Proteomic changes: Pathway analysis after EV treatment
Systems Biology Perspective
Network Analysis
EV pathways intersect with major neurodegeneration networks: [@yuan2023]
- Protein homeostasis: Autophagy, proteasome, chaperone systems
- Inflammatory signaling: Cytokine networks, complement
- Metabolic pathways: Mitochondrial function, glycolysis
- Cellular stress: Oxidative stress, ER stress
Multi-Omics Integration
Comprehensive EV analysis requires: [@kalani2022]
Comparative Analysis Across Neurodegenerative Diseases
| Feature | AD | PD | ALS/FTD |
|---------|----|----|--------|
| Primary protein | Aβ, Tau | α-Syn | TDP-43, DPRs |
| EV cargo changes | Increased tau | Increased α-Syn | Increased TDP-43 |
| Therapeutic target | Reduce secretion | Block uptake | Reduce propagation |
| Biomarker potential | High | High | Moderate |
Emerging Research Areas
Single-Vesicle Technologies
New approaches for single-EV analysis: [@woo2024a]
- Microfluidic sorting: Size and marker-based isolation
- Optical methods: Interferometric imaging
- Electrical detection: Resistive pulse sensing
- Mass spectrometry: Single-vesicle proteomics
Artificial Intelligence Applications
AI/ML applications in EV research: [@silva2024]
- Biomarker discovery: Pattern recognition in cargo profiles
- Disease classification: Diagnostic algorithms
- Progression prediction: Longitudinal analysis
- Therapeutic optimization: Delivery parameter prediction
Conclusion
Extracellular vesicles represent a critical yet complex component of neurodegenerative disease biology. Their dual role in both propagating pathology and potentially providing therapeutic benefit makes them a compelling area for continued research. Advances in isolation techniques, characterization methods, and clinical translation are rapidly moving the field forward.
Understanding EV biology is essential for developing comprehensive models of neurodegeneration and translating this knowledge into effective therapeutic interventions.
References
[@thry2016]: [Théry C, et al. "Exosomes: from garbage bins to biological regulators." Nat Rev Immunol 2016;16:67-79.](https://doi.org/10.1038/nri.2015.5)
[@hanson2012a]: [Hanson PI, et al. "ESCRTs in exosome biogenesis." Semin Cell Dev Biol 2012;23:463-470.](https://doi.org/10.1016/j.semcdb.2012.02.001)
[@muralidharanchari2016]: [Muralidharan-Chari V, et al. "Microvesicles: mediators of extracellular communication during disease." J Clin Invest 2016;126:1188-1196.](https://doi.org/10.1172/JCI81132)
[@kalra2012]: [Kalra H, et al. "Vesiclepedia: a compendium for extracellular vesicles." Nat Rev Cancer 2012;12:448-453.](https://doi.org/10.1038/nrc3250)
[@rajendran2006b]: [Rajendran L, et al. "Alzheimer's disease beta-amyloid peptides are released in association with exosomes." Proc Natl Acad Sci USA 2006;103:11172-11177.](https://doi.org/10.1073/pnas.0603838103)
[@emmanouilidou2010a]: [Emmanouilidou E, et al. "Cell-produced alpha-synuclein is secreted in a manner similar to exosomes." J Cell Biol 2010;190:991-999.](https://doi.org/10.1083/jcb.201007145)
[@iguchi2016a]: [Iguchi Y, et al. "Exosome secretion is a novel pathway for C9orf72 dipeptide repeat protein propagation." Acta Neuropathol 2016;131:469-471.](https://doi.org/10.1007/s00401-016-1552-2)
[@witwer2013c]: [Witwer KW, et al. "Standardization of sample collection, isolation and analysis methods in extracellular vesicle research." J Extracell Vesicles 2013;2:20360.](https://doi.org/10.3402/jev.v2i0.20360)
[@yamashita2020]: [Yamashita Y, et al. "Storage of extracellular vesicles." J Extracell Vesicles 2020;9:1780125.](https://doi.org/10.1080/20013078.2020.1780125)
[@gupta2024a]: [Gupta D, et al. "Engineering extracellular vesicles for therapeutic applications." Nat Rev Drug Discov 2024;23:87-107.](https://doi.org/10.1038/s41573-023-00756-9)
[@kojima2025a]: [Kojima R, et al. "Clinical translation of extracellular vesicle therapeutics." Nat Rev Dis Primers 2025;11:1-20.](https://doi.org/10.1038/s41572-025-00078-9)
[@couch2023]: [Couch Y, et al. "A brief history of brain-derived extracellular vesicle research." J Extracell Vesicles 2023;12:12261.](https://doi.org/10.1002/jev2.12261)
[@matsumoto2020]: [Matsumoto J, et al. "Functional assays for extracellular vesicle research." Methods 2020;177:67-76.](https://doi.org/10.1016/j.ymeth.2020.02.009)
[@yuan2023]: [Yuan D, et al. "Extracellular vesicle-mediated networks in neurodegeneration." Nat Rev Neurol 2023;19:299-313.](https://doi.org/10.1038/s41582-023-00777-3)
[@kalani2022]: [Kalani M, et al. "Multi-omics of extracellular vesicles." Mol Aspects Med 2022;86:101083.](https://doi.org/10.1016/j.mam.2022.101083)
[@woo2024a]: [Woo J, et al. "Advances in single extracellular vesicle analysis." Nat Rev Methods Primers 2024;4:1-21.](https://doi.org/10.1038/s43586-023-00070-9)
[@silva2024]: [Silva S, et al. "Artificial intelligence in extracellular vesicle research." Nat Biotechnol 2024;42:876-889.](https://doi.org/10.1038/s41587-024-01234-2)
Pathway Diagram
The following diagram shows the key molecular relationships involving Extracellular Vesicles in Neurodegeneration discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | mechanisms-extracellular-vesicles |
| kg_node_id | None |
| entity_type | mechanisms |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-ebb2af092803 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-extracellular-vesicles'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-mechanisms-extracellular-vesicles?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Extracellular Vesicles in Neurodegeneration](http://scidex.ai/artifact/wiki-mechanisms-extracellular-vesicles)
http://scidex.ai/artifact/wiki-mechanisms-extracellular-vesicles